Medical - Devices
Compare Stocks
5 / 10Stock Comparison
COCH vs LNTH vs MDT vs RMD vs BSX
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
COCH vs LNTH vs MDT vs RMD vs BSX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $13M | $6.06B | $97.62B | $30.12B | $80.15B |
| Revenue (TTM) | $241K | $1.55B | $35.48B | $5.54B | $20.07B |
| Net Income (TTM) | $-24M | $279M | $4.61B | $1.52B | $2.89B |
| Gross Margin | -262.7% | 60.5% | 61.9% | 61.7% | 69.0% |
| Operating Margin | -92.4% | 18.8% | 17.9% | 34.3% | 19.8% |
| Forward P/E | — | 17.7x | 13.8x | 18.6x | 16.0x |
| Total Debt | $919K | $738K | $28.52B | $852M | $12.42B |
| Cash & Equiv. | $4M | $359M | $2.22B | $1.21B | $2.04B |
COCH vs LNTH vs MDT vs RMD vs BSX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Envoy Medical, Inc. (COCH) | 100 | 6.5 | -93.5% |
| Lantheus Holdings, … (LNTH) | 100 | 392.7 | +292.7% |
| Medtronic plc (MDT) | 100 | 58.2 | -41.8% |
| ResMed Inc. (RMD) | 100 | 110.0 | +10.0% |
| Boston Scientific C… (BSX) | 100 | 123.7 | +23.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COCH vs LNTH vs MDT vs RMD vs BSX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
COCH ranks third and is worth considering specifically for dividends.
- 14.7% yield, vs MDT's 3.7%, (2 stocks pay no dividend)
LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 42.9% 10Y total return vs RMD's 293.5%
- Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
- +15.7% vs COCH's -58.3%
MDT has the current edge in this matchup, primarily because of its strength in income & stability and defensive.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Beta 0.42, yield 3.7%, current ratio 1.85x
- Lower P/E (13.8x vs 16.0x)
- 175.8% ROA vs COCH's -256.7%
RMD is the clearest fit if your priority is valuation efficiency.
- PEG 1.07 vs MDT's 35.17
- 27.4% margin vs COCH's -98.6%
BSX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
- 19.9% revenue growth vs LNTH's 0.5%
- Beta 0.30 vs COCH's 0.95
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.9% revenue growth vs LNTH's 0.5% | |
| Value | Lower P/E (13.8x vs 16.0x) | |
| Quality / Margins | 27.4% margin vs COCH's -98.6% | |
| Stability / Safety | Beta 0.30 vs COCH's 0.95 | |
| Dividends | 14.7% yield, vs MDT's 3.7%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +15.7% vs COCH's -58.3% | |
| Efficiency (ROA) | 175.8% ROA vs COCH's -256.7% |
COCH vs LNTH vs MDT vs RMD vs BSX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
COCH vs LNTH vs MDT vs RMD vs BSX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RMD leads in 1 of 6 categories
MDT leads 1 • LNTH leads 1 • COCH leads 0 • BSX leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 147236.5x COCH's $241,000. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to COCH's -98.6%. On growth, COCH holds the edge at +78.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $241,000 | $1.5B | $35.5B | $5.5B | $20.1B |
| EBITDAEarnings before interest/tax | -$22M | $347M | $9.4B | $2.1B | $4.7B |
| Net IncomeAfter-tax profit | -$24M | $279M | $4.6B | $1.5B | $2.9B |
| Free Cash FlowCash after capex | -$18M | $372M | $5.4B | $1.8B | $3.6B |
| Gross MarginGross profit ÷ Revenue | -2.6% | +60.5% | +61.9% | +61.7% | +69.0% |
| Operating MarginEBIT ÷ Revenue | -92.4% | +18.8% | +17.9% | +34.3% | +19.8% |
| Net MarginNet income ÷ Revenue | -98.6% | +18.0% | +13.0% | +27.4% | +14.4% |
| FCF MarginFCF ÷ Revenue | -76.3% | +24.0% | +15.2% | +31.7% | +18.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +78.6% | +1.2% | +8.8% | +10.8% | +15.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | +76.5% | -11.9% | +9.3% | +18.5% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 24% valuation discount to BSX's 27.8x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13M | $6.1B | $97.6B | $30.1B | $80.1B |
| Enterprise ValueMkt cap + debt − cash | $10M | $5.7B | $123.9B | $29.8B | $90.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.51x | 27.29x | 21.09x | 21.74x | 27.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.70x | 13.80x | 18.61x | 15.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 35.17x | 1.25x | — |
| EV / EBITDAEnterprise value multiple | — | 14.96x | 14.06x | 15.49x | 24.25x |
| Price / SalesMarket cap ÷ Revenue | 54.66x | 3.93x | 2.91x | 5.85x | 3.99x |
| Price / BookPrice ÷ Book value/share | — | 5.84x | 2.04x | 5.10x | 3.29x |
| Price / FCFMarket cap ÷ FCF | — | 17.11x | 18.83x | 18.13x | 21.91x |
Profitability & Efficiency
Evenly matched — LNTH and RMD each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $9 for MDT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs COCH's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +24.3% | +9.4% | +24.4% | +12.4% |
| ROA (TTM)Return on assets | -2.6% | +12.4% | +175.8% | +18.0% | +6.9% |
| ROICReturn on invested capital | — | +30.6% | +6.0% | +22.8% | +8.8% |
| ROCEReturn on capital employed | -44.7% | +17.1% | +7.5% | +25.7% | +11.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 8 | 7 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.59x | 0.14x | 0.51x |
| Net DebtTotal debt minus cash | -$3M | -$358M | $26.3B | -$358M | $10.4B |
| Cash & Equiv.Liquid assets | $4M | $359M | $2.2B | $1.2B | $2.0B |
| Total DebtShort + long-term debt | $919,000 | $738,000 | $28.5B | $852M | $12.4B |
| Interest CoverageEBIT ÷ Interest expense | -5.82x | 15.83x | 9.08x | 66.06x | 11.03x |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $651 for COCH. Over the past 12 months, LNTH leads with a +15.7% total return vs COCH's -58.3%. The 3-year compound annual growth rate (CAGR) favors BSX at 0.5% vs COCH's -60.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.0% | +38.3% | -20.0% | -15.3% | -43.1% |
| 1-Year ReturnPast 12 months | -58.3% | +15.7% | -5.5% | -14.0% | -47.8% |
| 3-Year ReturnCumulative with dividends | -93.7% | -1.9% | -6.3% | -8.4% | +1.5% |
| 5-Year ReturnCumulative with dividends | -93.5% | +338.1% | -29.2% | +12.0% | +24.7% |
| 10-Year ReturnCumulative with dividends | -93.5% | +4289.6% | +24.3% | +293.5% | +143.6% |
| CAGR (3Y)Annualised 3-year return | -60.3% | -0.6% | -2.1% | -2.9% | +0.5% |
Risk & Volatility
Evenly matched — LNTH and BSX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSX is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than COCH's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs COCH's 33.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.45x | 0.42x | 0.65x | 0.30x |
| 52-Week HighHighest price in past year | $1.91 | $94.86 | $106.33 | $293.81 | $109.50 |
| 52-Week LowLowest price in past year | $0.36 | $47.25 | $75.91 | $198.64 | $53.64 |
| % of 52W HighCurrent price vs 52-week peak | +33.2% | +98.1% | +71.6% | +70.4% | +49.3% |
| RSI (14)Momentum oscillator 0–100 | 45.3 | 69.9 | 29.2 | 33.3 | 35.4 |
| Avg Volume (50D)Average daily shares traded | 235K | 872K | 7.9M | 1.1M | 15.6M |
Analyst Outlook
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LNTH as "Buy", MDT as "Buy", RMD as "Buy", BSX as "Buy". Consensus price targets imply 69.3% upside for BSX (target: $91) vs 6.7% for LNTH (target: $99). For income investors, COCH offers the higher dividend yield at 14.65% vs RMD's 1.02%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $99.25 | $109.50 | $281.29 | $91.33 |
| # AnalystsCovering analysts | — | 17 | 49 | 35 | 43 |
| Dividend YieldAnnual dividend ÷ price | +14.7% | — | +3.7% | +1.0% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 36 | 14 | 0 |
| Dividend / ShareAnnual DPS | $0.09 | — | $2.78 | $2.11 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.0% | +3.3% | +1.0% | 0.0% |
RMD leads in 1 of 6 categories (Income & Cash Flow). MDT leads in 1 (Valuation Metrics). 3 tied.
COCH vs LNTH vs MDT vs RMD vs BSX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is COCH or LNTH or MDT or RMD or BSX a better buy right now?
For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.
9% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — COCH or LNTH or MDT or RMD or BSX?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Boston Scientific Corporation at 27. 8x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 07x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — COCH or LNTH or MDT or RMD or BSX?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +338. 1%, compared to -93. 5% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — COCH or LNTH or MDT or RMD or BSX?
By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.
30β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 218% more volatile than BSX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — COCH or LNTH or MDT or RMD or BSX?
By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.
9% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — COCH or LNTH or MDT or RMD or BSX?
ResMed Inc.
(RMD) is the more profitable company, earning 27. 2% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -92. 4% for COCH. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is COCH or LNTH or MDT or RMD or BSX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 07x versus Medtronic plc's 35. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 18. 6x for ResMed Inc. — 4. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 69. 3% to $91. 33.
08Which pays a better dividend — COCH or LNTH or MDT or RMD or BSX?
In this comparison, COCH (14.
7% yield), MDT (3. 7% yield), RMD (1. 0% yield) pay a dividend. LNTH, BSX do not pay a meaningful dividend and should not be held primarily for income.
09Is COCH or LNTH or MDT or RMD or BSX better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, COCH: -93. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between COCH and LNTH and MDT and RMD and BSX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: COCH is a small-cap income-oriented stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; RMD is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. COCH, MDT, RMD pay a dividend while LNTH, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.